Tara Nikonow Morgan

Dr. Tara Nikonow Morgan

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Current Urology Reports
Verified
Journal Article
Closed access
PDF file
AGAlaina Garbens
Alaina Garbens
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu

1 June 2018 in Journal of Endourology
Verified
Journal Article
Closed access
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
Mohammed ShahaitMohammed Shahait
Mohammed Shahait
AMAvinash Maganty
Avinash Maganty
MOMichael C Ost
Michael C Ost
SJStephen V Jackman
Stephen V Jackman
MSMichelle Jo Semins
Michelle Jo Semins
Background: To describe the clinical characteristics, infectious and kidney function patterns, and overall outcomes in a cohort of patients with staghorn calculi treated conservatively. Methods: Staghorn calculi treated non-operatively between January 2009 and January 2017 were identified. A retrospective analysis was completed. Results: Twenty-nine patients were identified with median age of 74 (IQR 61-81). Mean follow-up was 24 months. Fifty nine percent (17/29) had complete staghorn calculi with 6/29 (21%) bilateral. Mean body mass index was 29.4 (IQR 24.8-31.7). Of the 29 patients, 14 were treated conservatively due to comorbidities, 12 refused treatments, and 3 were due to aberrant anatomy. The Age-Adjusted Charlson Comorbidity Index Score (CCI) demonstrated 8 patients in our cohort with a CCI of 8. Overall, kidney function remained stable for 19/29 patients (66%), GFR decreased by 30% for 4/29 patients (14%) over the study period. None of the study patients required hemodialysis. No patients in the cohort developed an abscess, nor were any patients on daily prophylactic antibiotics. There was only 1 related admission for a complication during the study; this was for pyelonephritis. There were two deaths during the study period. One death was unrelated cardiac death and the other was from urosepsis; this patient had been noncompliant with follow up. Conclusion: Outcomes for patients treated conservatively were reasonable in this select group. There is a need for future, prospective studies to show whether conservative treatment of these patients is safe.

1 November 2021 in Journal of Endourology
Verified
Journal Article
Closed access
JDJessica C. Dai
Jessica C. Dai
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
RSRyan L. Steinberg
Ryan L. Steinberg
BJBrett Allen Johnson
Brett Allen Johnson
AGAlaina Garbens
Alaina Garbens
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu
Introduction: Irreversible electroporation (IRE) is a nonthermal ablative technology that applies high-voltage short-pulse electrical current to create cellular membrane nanopores and ultimately results in apoptosis. This is thought to overcome thermal limitations of other ablative technologies. We report 5-year oncologic outcomes of percutaneous IRE for small renal masses. Patients and Methods: A single-institution retrospective review of cT1a renal masses treated with IRE from April 2013 to December 2019 was performed. Those with <1 month follow-up were excluded. IRE was performed with the NanoKnife © System (Angiodynamics, Latham, NY). Renal mass biopsy was obtained before or during ablation in most circumstances; biopsy was excluded in some patients because of concern for IRE probe displacement. Postablation guideline-based surveillance imaging was performed. Initial treatment failure was defined as persistent tumor enhancement on first post-treatment imaging. Survival analysis was performed through the Kaplan–Meier method for effectively treated tumors (SPSS; IBM, Armonk, NY). Results: IRE was used to treat 48 tumors in 47 patients. Twenty-two per 48 tumors (45.8%) were biopsy-confirmed renal cell carcinoma (RCC). No complications ≥ Clavien Grade III occurred and 36 patients (76.6%) were discharged the same day. Initial treatment success rate was 91.7% ( n = 44/48); three treatment failures were managed with salvage radiofrequency ablation and one with robotic partial nephrectomy. Median follow-up was 50.4 months (interquartile range 29.0–65.5). The 5-year local recurrence-free survival was 81.4% in biopsy-confirmed RCC patients and 81.0% in all patients. Five-year metastasis-free survival was 93.3% and 97.1%, respectively, and 5-year overall survival was 92.3% and 90.6%, respectively. Five-year cancer-specific survival was 100% for both biopsy-confirmed RCC and all patient groups. Conclusions: IRE has low morbidity, but suboptimal intermediate-term oncologic outcomes compared with conventional thermal ablation techniques for small low-complexity tumors. Use of IRE should be restricted to select cases.

1 January 2022 in Urology
Verified
Journal Article
Closed access
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
JDJessica C. Dai
Jessica C. Dai
SKSam Kusin
Sam Kusin
VKVineeth Kommidi
Vineeth Kommidi
AGAlaina Garbens
Alaina Garbens
JCJeffrey A. Cadeddu
Jeffrey A. Cadeddu

1 September 2023 in Journal of Endourology
Verified
Journal Article
Closed access
ALAustin J. Livingston
Austin J. Livingston
TDThomas Dvergsten
Thomas Dvergsten
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
Background: There is a paucity of guidelines for prostate-specific antigen (PSA) monitoring after simple prostatectomy (SP) despite these patients remaining at risk for prostate cancer (PCa). Our objective was to determine if PSA kinetics can be a potential indicator of PCa after SP. Methods: A retrospective review was performed of all simple prostatectomies at our institution from 2014 to 2022. All patients who met criteria were included in the study. Relevant clinical variables were collected preoperatively, including PSA value, prostate size, and voiding symptoms. Surgical and urinary function outcomes were analyzed. Results: A total of 92 patients were divided into two groups based on malignancy status. Sixty-eight patients did not have PCa, while 24 patients had known PCa before surgery (14) or were diagnosed as having incidental PCa from the pathological specimen (10). Patients with benign prostates had an initial postoperative PSA value of 0.76 ng/mL compared with 1.68 ng/mL for those with cancer ( p < 0.01). PSA velocity for the first 24 months after surgery was 0.042 ± 1.61 ng/(mL·year) for the benign cohort compared with 1.29 ± 1.02 ng/(mL·year) for the malignant cohort ( p = 0.01). Voiding improvements were noted by objective (postvoid residual and flow rate) and subjective (American Urological Association symptom score and quality of life score) measures in both groups. Conclusions: PSA interpretation and monitoring after SP have not been well established. Our study indicates that initial postoperative PSA value and PSA velocity are important indicators of underlying malignancy in patients after SP. Further efforts are needed to establish threshold values and formal guidelines.

7 February 2020 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
KSKatherine Shapiro
Katherine Shapiro
NPNatalie Pace
Natalie Pace
Tara Nikonow MorganTara Nikonow Morgan
Tara Nikonow Morgan
HCHaotian Cai
Haotian Cai
BSBing Shen
Bing Shen
CTChangfeng Tai
Changfeng Tai
Objective: To determine the inhibitory effect on bladder activity induced by bilateral pudendal neuromodulation. Methods: In 10 cats under anesthesia, two tripolar cuff electrodes were implanted bilaterally on the pudendal nerves for stimulation. A double lumen catheter was inserted into the bladder through the urethra to infuse saline and measure bladder pressure. During repeated cystometrograms (CMGs) pudendal nerve stimulation (PNS: 5 Hz, 0.2 ms, 5–15 min) was applied unilaterally or bilaterally at 1- or 2-times intensity threshold (T) for inducing anal sphincter twitching. PNS inhibition was indicated by the increase in bladder capacity measured by CMGs. Results: Unilateral PNS at 1T did not significantly increase bladder capacity, but at 2T significantly (p < 0.05) increased bladder capacity by about 30%. Bilateral PNS at 1T also failed to increase bladder capacity, but at 2T significantly (p < 0.05) increased bladder capacity by about 60%, indicating an additive effect induced by the bilateral 2T PNS. Unilateral 1T PNS did not enhance the inhibitory effect induced by contra-lateral 2T PNS. Conclusion: This study in anesthetized cats reveals that an additive inhibition of reflex bladder activity can be induced by bilateral pudendal neuromodulation, indicating that bilateral PNS might achieve better therapeutic efficacy in treating overactive bladder (OAB) than unilateral PNS.